Lepotex
Categorie
Lepotex Les marques, Lepotex Analogs
Lepotex Les marques melange
Lepotex Formule chimique
C18H19ClN4
Lepotex RX lien
http://www.rxlist.com/cgi/generic3/clozapine.htm
Lepotex FDA fiche
Lepotex msds (fiche de securite des materiaux)
Lepotex Synthese de reference
Aucune information disponible
Lepotex Poids moleculaire
326.823 g/mol
Lepotex Point de fusion
183-184 oC
Lepotex H2O Solubilite
11,8 mg / L
Lepotex Etat
Solid
Lepotex LogP
2.502
Lepotex Formes pharmaceutiques
Tablet
Lepotex Indication
Pour la gestion des patients schizophrènes gravement malades qui ne répondent pas adéquatement aux traitements médicamenteux standard pour la schizophrénie
Lepotex Pharmacologie
La clozapine est un agent psychotrope appartenant à la classe chimique des dérivés benzisoxazole et est indiqué pour le traitement de la schizophrénie. La clozapine est un antagoniste sélectif des monoaminergiques forte affinité pour le type 2 la sérotonine (5HT2), type dopamine 2 (D2), 1 et 2 adrénergiques et histaminergiques H1. La clozapine agit comme un antagoniste des récepteurs d'autres, mais avec une puissance inférieure. Antagonisme au niveau des récepteurs autres que la dopamine et des récepteurs 5HT2 qui ont des affinités similaires peuvent expliquer certains des effets d'autres thérapeutiques et secondaires de la clozapine. La clozapine antagonisme de muscariniques M1-5 récepteurs peuvent expliquer ses effets anticholinergiques. L'antagonisme des récepteurs de la clozapine histamine H1 peut expliquer la somnolence observée avec ce médicament. L'antagonisme de la clozapine récepteurs adrénergiques a1 peut expliquer la l'hypotension orthostatique observée avec ce médicament.
Lepotex Absorption
Rapide et presque complète
Lepotex Toxicite
Aucune information disponible
Lepotex Information pour les patients
PATIENT INFORMATION
� Patients who are to receive CLOZARIL should be warned about the significant risk of developing agranulocytosis. They should be informed that weekly blood tests are required for the first 6 months, if acceptable WBC counts (WBC � 3000/mm3, ANC � 1500/mm3) have been maintained during the first 6 months of continuous therapy, then WBC counts can be monitored every other week in order to monitor for the occurrence of agranulocytosis, and that CLOZARIL tablets will be made available only through a special program designed to ensure the required blood monitoring. Patients should be advised to report immediately the appearance of lethargy, weakness, fever, sore throat, malaise, mucous membrane ulceration or other possible signs of infection.
Particular attention should be paid to any flu-like complaints or other symptoms that might suggest infection.
� Patients should be informed of the significant risk of seizure during CLOZARIL treatment, and they should be advised to avoid driving and any other potentially hazardous activity while taking CLOZARIL.
� Patients should be advised of the risk of orthostatic hypotension, especially during the period of initial dose titration.
� Patients should be informed that if they stop taking CLOZARIL for more than 2 days, they should not restart their medication at the same dosage, but should contact their physician for dosing instructions.
� Patients should notify their physician if they are taking, or plan to take, any prescription or over-the-counter drugs or alcohol.
� Patients should notify their physician if they become pregnant or intend to become pregnant during therapy.
� Patients should not breast-feed an infant if they are taking CLOZARIL.
� Patients who are to receive CLOZARIL should be warned about the significant risk of developing agranulocytosis. They should be informed that weekly blood tests are required for the first 6 months, if acceptable WBC counts (WBC � 3000/mm3, ANC � 1500/mm3) have been maintained during the first 6 months of continuous therapy, then WBC counts can be monitored every other week in order to monitor for the occurrence of agranulocytosis, and that CLOZARIL tablets will be made available only through a special program designed to ensure the required blood monitoring. Patients should be advised to report immediately the appearance of lethargy, weakness, fever, sore throat, malaise, mucous membrane ulceration or other possible signs of infection.
Particular attention should be paid to any flu-like complaints or other symptoms that might suggest infection.
� Patients should be informed of the significant risk of seizure during CLOZARIL treatment, and they should be advised to avoid driving and any other potentially hazardous activity while taking CLOZARIL.
� Patients should be advised of the risk of orthostatic hypotension, especially during the period of initial dose titration.
� Patients should be informed that if they stop taking CLOZARIL for more than 2 days, they should not restart their medication at the same dosage, but should contact their physician for dosing instructions.
� Patients should notify their physician if they are taking, or plan to take, any prescription or over-the-counter drugs or alcohol.
� Patients should notify their physician if they become pregnant or intend to become pregnant during therapy.
� Patients should not breast-feed an infant if they are taking CLOZARIL.
Lepotex Organismes affectes
Les humains et autres mammifères
